Quantum News
Sign InSign Up
Back to News
research

Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Precigen launched PAPZIMEOS in early 2026, the first FDA-approved immunotherapy for adult recurrent respiratory papillomatosis (RRP), marking its transition to a commercial-stage biotech company. The drug leverages Precigen’s proprietary AdenoVerse platform, a fully owned technology designed to target RRP—a rare, debilitating condition causing recurrent airway tumors. CEO Helen Sabzevari highlighted PAPZIMEOS’s innovation, emphasizing its potential to address unmet medical needs for adult RRP patients, who previously lacked approved immunotherapies. Chief Commercial Officer Phil Tennant outlined early launch strategies, focusing on market differentiation and patient access, though specific commercial performance details were not disclosed. The March 2026 fireside chat underscored Precigen’s shift from R&D to commercialization, with analysts probing the drug’s mechanism and competitive positioning in the niche RRP treatment landscape.
AI Audio Summary
0:00 / 0:00
Click to play
7324336a-a9e8-4a04-a1d0-da740cf7a617.jpeg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.17K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP March 31, 2026 11:00 AM EDT Company Participants Helen Sabzevari - President, CEO & DirectorPhil Tennant - Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Swayampakula RamakanthH.C. Wainwright & Co, LLC, Research Division Good morning. I'm RK, a senior sell-side biotech analyst at H.C. Wainwright. So -- and we are thrilled to be hosting Precigen for this fireside chat this morning. So 2025 has been a transformational year for Precigen, marked by the landmark FDA approval of PAPZIMEOS, the first immunotherapy for adult RRP. So as we sit here in late March of 2026, the company has officially transitioned into a commercial stage entity reporting its first quarter of launch very recently. So joining us today are Dr. Helen Sabzevari, President and CEO; and Phil Tennant, Chief Commercial Officer. Good morning, folks, and thank you very much for joining us this morning. Question-and-Answer Session Swayampakula RamakanthH.C. Wainwright & Co, LLC, Research Division Helen, as we get started, especially with your experience of developing various therapies. And now with this particular one, PAPZIMEOS. So how do you see this new excursion with this drug. And also, if you can, please describe the molecule itself and what it does for this particular set of patients? Helen SabzevariPresident, CEO & Director Well, first of all, I would like to take the opportunity to thank you, RK, for having us and also to say good morning to the audience here. Clearly, the PAPZIMEOS molecule at the center of all of this for the recurrent respiratory Papillomatosis is a very innovative molecule and the premise of this molecule is built on AdenoVerse platform that we have at Precigen, which, by the way, we fully have the ownership of

Read Original

Tags

government-funding

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.